Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States[8] and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.Belimumab is indicated for the treatment of active systemic lupus erythematosus and active lupus nephritis.<\/p>\n
\u2022 BENLYSTA is a prescription medicine used to treat people with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (lupus-related kidney inflammation), who are receiving other lupus medicines.
\n\u2022 BENLYSTA contains belimumab which is in a group of medicines called monoclonal antibodies. Lupus is a disease of the immune system (the body system that fights infection). When given together with other medicines for lupus, BENLYSTA decreases lupus disease activity more than other lupus medicines alone.<\/p>\n
If Belimumab Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Note:<\/strong> BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: Active ingredient: belimumab. Inactive ingredients (intravenous): citric acid, polysorbate 80, sodium citrate, sucrose. Inactive Ingredients (subcutaneous): L-arginine hydrochloride, L-histidine, L-histidine monohydrochloride, polysorbate 80, sodium chloride.<\/p>\n Approval Date: 2011 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import Belimumab Injection\u201d based on the information you provide.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\nReferences<\/h3>\n
\n
\nSee Drugs@FDA for information about all of CDER\u2019s approved drugs and biological products.<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"BENLYSTA (belimumab) injection,
\nfor subcutaneous use Initial U.S. Approval: 2011<\/h2>\n
\n\u2022 patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy;
\n\u2022 patients aged 5 years and older.<\/p>\nFacts about Belimumab Injection<\/h4>\n
\nProprietary Name: On Request
\nActive Ingredient(s): Belimumab Injection
\nDosage Forms And Strengths: \u2022 Intravenous Infusion: \u2212 For Injection: 120 mg or 400 mg of belimumab lyophilized powder in single-dose vial for reconstitution and dilution prior to intravenous infusion. \u2022 Subcutaneous Injection: \u2212Injection: 200 mg\/mL of belimumab in single-dose prefilled autoinjector or single-dose prefilled syringe.
\n<\/strong>International non-proprietary name (INN) or common name: Belimumab Injection
\nTherapeutic area (MeSH): active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (lupus-related kidney inflammation)
\nMarketing: GlaxoSmithKline
\nEMA Approved: 2011
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a><\/p>\nAccess the best support services globally<\/h4>\n